THE VILLAGES, Fla., Oct. 25, 2024 /PRNewswire/ -- K2 Medical Research is proud to announce a significant milestone in the fight against Alzheimer's disease: the successful randomization of the first patient in the world for the J&J ReTain study. This groundbreaking clinical trial aims to evaluate the effects of an investigational medication on cognitive decline in pre-clinical Alzheimer's disease (AD).

The ReTain trial is designed to explore how this novel treatment impacts not only cognitive functions but also the accumulation of tau protein in the brain, a key marker associated with Alzheimer's progression. Utilizing advanced tau PET imaging, researchers will gather crucial data on how the investigational medication may alter the trajectory of cognitive decline and tau accumulation in participants.

"This is an exciting moment for our team and the broader research community," said Dr. Craig Curtis, Principal Investigator at K2 Medical Research. "By being the first site to randomize a patient in the ReTain study, we are taking an important step towards understanding and potentially mitigating the effects of Alzheimer's disease."

The ReTain study is part of a larger initiative to develop effective therapies for individuals at risk for onset of Alzheimer's disease symptoms. As the global population ages, the need for innovative research in this area has never been more urgent. The findings from this study could pave the way for new treatment strategies that may improve the quality of life for millions affected by this debilitating disease.

K2 Medical Research is committed to advancing medical knowledge and improving patient outcomes through rigorous clinical trials and innovative research methodologies.

For more information about the J&J ReTain study or to learn how to participate, please visit our website at www.k2med.com or contact our research team directly.

About K2 Medical Research

K2 Medical Research is a leading clinical research organization with locations in The Villages, Florida, Central Florida and Tampa, dedicated to conducting high-quality research in the fields of neurology and other medical specialties. Our mission is to bring new treatments to patients through innovative studies and collaborative partnerships.

Contact: 

Sandra Carmona Torres
Executive Director, Patient Engagement, Marketing and Diversity
K2 Medical Research
Phone: 407-818-1957
Email: sandra.torres@k2med.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/k2-medical-research-the-villages-achieves-landmark-milestone-in-alzheimers-research-302287541.html

SOURCE K2 Medical Research